Publications

onc201

Safety of ONC201 administered two consecutive days per week in pediatric H3 K27M-mutant glioma patients

2021 SNO Annual Meeting Abstract CTNI-36

Sharon L. Gardner, M.D., New York University School of Medicine

onc201

Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients

2021 SNO Annual Conference

Isabel Arrillaga-Romany, M.D., Ph. D., Massachusetts General Hospital

onc206

IND-enabling characterization of dual DRD2-and ClpP-targeting agent ONC206 as the next imipridone for clinical neuro-oncology

Neuro-Oncology 2020

Prabhu V, Morrow S, Kawakibi AR, et al.

onc206

Predictive biomarker evaluation and molecular differentiation for imipridones ONC201 and ONC206

AACR annual meeting 2021, Abstract Number: 393

Morrow S, Nath K, Zhang Y, et al.

imipridones

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

Neoplasia 2020 PMID: 33142238

Prabhu VV, Morrow S, Kawakibi AR, et al.

onc206

Targeting dopamine receptor D2 by imipridone suppresses uterine serous cancer malignant phenotype

Cancers (Basel). 2020 PMID: 32867127

Hu W, Zhang L, Ferri-Borgogno S, et al.

onc201

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors

Neuro Oncol. 2021 PMID: 32830856

He Y, Li J, Koga T, et al.

imipridones

Metabolic reprogramming by dual AKT/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma

Clin Cancer Res. 2018 PMID: 30037819

Ishida CT, Zhang Y, Bianchetti E, et al.

onc201

A Bayesian machine learning approach for drug target identification using diverse data types

Nat Commun. 2019 PMID: 31745082

Madhukar NS, Khade PK, Huang L, et al.

uncategorized

Updated study results of CX-01, an inhibitor of CXCL12/CXCR4, and azacitidine for the treatment of hypomethylating agent refractory AML and MDS

Blood 2019

Huselton, Eric, Amanda F. Cashen, John F. DiPersio, et al.